Format

Send to

Choose Destination
Crit Rev Clin Lab Sci. 2017 Mar;54(2):87-101. doi: 10.1080/10408363.2016.1261270. Epub 2016 Dec 26.

Biomarkers for monitoring chemotherapy-induced cardiotoxicity.

Author information

1
a Department of Laboratory Medicine , Unit 37, The University of Texas MD Anderson Cancer Center , Houston , TX , USA and.
2
b Department of Biomedical Engineering , University of Alabama at Birmingham , Birmingham , AL , USA.

Abstract

Cardiotoxicity, including acute and late-onset cardiotoxicity, is a well-known adverse effect of many types of antitumor agents. Early identification of patients with cardiotoxicity is important to ensure prompt treatment and minimize toxic effects. The etiology of chemotherapy-induced cardiotoxicity is multifactorial. Traditional methods for assessment of chemotherapy-induced cardiotoxicity typically involve serial measurements of cardiac function via multi-modality imaging techniques. Typically, however, significant left ventricular dysfunction has already occurred when cardiotoxicity is detected by imaging techniques. Biomarkers, most importantly cardiac natriuretic peptides and troponins, are promising markers for identifying patients potentially at risk for clinical heart failure symptoms. This review summarizes the recent progress in clinical utilization of biomarkers for early diagnosis of acute cardiotoxicity and for prediction of late-onset cardiotoxicity. We also discuss the conflicting results of different studies and the association of results with study design.

KEYWORDS:

Biomarker; cardiotoxicity; chemotherapy

PMID:
28013560
DOI:
10.1080/10408363.2016.1261270
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center